How much does a box of genuine avatrombopag cost?

Avatrombopag is an oral thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adults with chronic liver disease requiring surgery. Patients with chronic liver disease often have thrombocytopenia, which may increase surgical risk because thrombocytopenia leads to an increased risk of intraoperative bleeding. Avatrombopag increases platelet production by stimulating thrombopoietin receptors, thereby increasing platelet counts and reducing the risk of bleeding before and after surgery.

Avatrombopag has now been officially launched in China and has been included in the national medical insurance system. Therefore, patients can directly purchase the drug in China, and the estimated price is approximately RMB 3,000 to 4,000. Regarding the specific selling price and details of medical insurance reimbursement, patients are advised to consult the pharmacy of their local hospital to obtain the most accurate information. It is worth mentioning that the price of foreign generic drugs of avatrombopag is more affordable. The main listing locations include Laos and Bangladesh, and its price is only a few hundred to one thousand yuan. The ingredients of these generic drugs are basically the same as those of the original drugs.

The drug's mechanism of action involves binding to the thrombopoietin receptor (TPOreceptor), promoting the production and release of platelets in the bone marrow. Its binding to the TPO receptor activates signaling pathways that promote the differentiation of platelet precursor cells into mature platelets and their release into the circulation.

Avatrombopag is usually taken as an oral medication, and the dosage and frequency of use depend on the patient's specific condition and the recommendations of the clinician. Before surgery, doctors may determine the most appropriate dose and duration of use based on the patient's platelet count and surgical risks.

However, like all medications, avatrombopag may cause side effects, including headache, nausea, and diarrhea. During use, patients should pay close attention to any adverse reactions and report them to their doctor in a timely manner.

In general, avatrombopag, as an oral thrombopoietin receptor agonist, has important clinical significance in the treatment of preoperative thrombocytopenia in patients with chronic liver disease, but it needs to be closely monitored during use and used rationally under the guidance of a doctor.